Skip to content

Revolutions Medical CORP: 10-K/A filed 2011-09-16

What Revolutions Medical CORP reported in its annual report amendment filed 2011-09-16 (fiscal FY 2010): 22 published measures, 78 facts as tagged in accession 0001144204-11-053539.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-K/A (annual report amendment)
Filed
2011-09-16
Fiscal period
fiscal FY 2010
Accession
0001144204-11-053539 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Revolutions Medical CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2010-12-311,234,028USD
At 2009-12-31156,051USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2010-12-311,581,108USD
At 2009-12-31604,837USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2010-12-31-347,080USD
At 2009-12-31-448,786USD
At 2008-12-31-1,740,143USD
At 2007-12-31-1,645,612USD
At 2006-12-31-1,427,270USD
At 2005-12-31-480,902USD
At 2004-12-31-1,108,531USD
At 2003-12-31-820,473USD
At 2002-12-31-147,815USD
At 2001-12-31236,263USD
At 2000-12-3147,327USD
At 1999-12-31739,798USD
At 1998-12-31742,201USD
At 1997-12-31890,808USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2010-01-01 to 2010-12-31-2,575,284USD365
1996-08-16 to 2010-12-31-25,576,750USD5251
2009-01-01 to 2009-12-31-2,463,751USD365
2008-01-01 to 2008-12-31-1,335,154USD366
2007-01-01 to 2007-12-31-4,475,017USD365
2006-01-01 to 2006-12-31-598,302USD365
2005-01-01 to 2005-12-31-1,310,783USD365
2004-01-01 to 2004-12-31-1,552,008USD366
2003-01-01 to 2003-12-31-1,391,519USD365
2002-01-01 to 2002-12-31-1,933,676USD365
2001-01-01 to 2001-12-31-2,199,085USD365
2000-01-01 to 2000-12-31-1,347,859USD366
1999-01-01 to 1999-12-31-4,014,555USD365
1998-01-01 to 1998-12-31-2,584,383USD365
1996-08-16 to 1997-12-31-795,376USD503

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2010-01-01 to 2010-12-31-1,208,524USD365
1996-08-16 to 2010-12-31-8,108,511USD5251
2009-01-01 to 2009-12-31-1,156,289USD365

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2010-01-01 to 2010-12-31782,375USD365
1996-08-16 to 2010-12-31889,102USD5251
2009-01-01 to 2009-12-3139,685USD365

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2010-01-01 to 2010-12-3112,640USD365
1996-08-16 to 2010-12-31183,393USD5251

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2010-01-01 to 2010-12-311,993,188USD365
1996-08-16 to 2010-12-319,561,694USD5251
2009-01-01 to 2009-12-311,283,406USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2010-01-01 to 2010-12-31-782,375USD365
1996-08-16 to 2010-12-31-1,186,099USD5251
2009-01-01 to 2009-12-31-64,685USD365

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2010-12-31812,478USD
At 2009-12-3136,151USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
1996-08-16 to 2010-12-312,018,280USD5251
2009-01-01 to 2009-12-311,452,231USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2010-01-01 to 2010-12-31-2,360,314USD365
1996-08-16 to 2010-12-31-25,291,919USD5251
2009-01-01 to 2009-12-31-2,300,439USD365

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2010-01-01 to 2010-12-31166,671USD365
1996-08-16 to 2010-12-31285,112USD5251

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2010-12-311,581,108USD
At 2009-12-31604,837USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2010-12-3148,277USD
At 2009-12-3152,672USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2010-01-01 to 2010-12-31969USD365
1996-08-16 to 2010-12-31969USD5251

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2010-01-01 to 2010-12-312,372,954USD365
1996-08-16 to 2010-12-3125,475,312USD5251
2009-01-01 to 2009-12-312,300,439USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2010-01-01 to 2010-12-31257,350USD365
1996-08-16 to 2010-12-312,843,406USD5251
2009-01-01 to 2009-12-31303,000USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2010-12-3142,869,909shares
At 2009-12-3135,197,891shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2010-12-3125,186,271USD
At 2009-12-3122,515,983USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2010-01-01 to 2010-12-312,109,556USD365
1996-08-16 to 2010-12-3119,237,274USD5251
2009-01-01 to 2009-12-311,993,905USD365

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2010-01-01 to 2010-12-316,049USD365
1996-08-16 to 2010-12-3185,107USD5251
2009-01-01 to 2009-12-313,534USD365

Inspect the source

Entity
Revolutions Medical CORP / CIK 0001041009
Captured
SEC response SHA-256
147399b6fb66b811b6d2c30d5167ca16121e9239b95a8a07106a6bdf6bbf37d5

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001041009.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))